Prolongated and large dose of r-ATG relieves PD-L1 inhibitor-induced allograft rejection in liver transplant recipient  

作　　者：Yi-Jie Zhang Dian-Jie Zhou Hong Li Qi Pan Ying Cheng 

机构地区：[1]Department of Hepatobiliary Surgery and Organ Transplantation,the First Affiliated Hospital of China Medical University,Shenyang 110001,China

出　　处：《Hepatobiliary & Pancreatic Diseases International》2025年第2期221-224,共4页国际肝胆胰疾病杂志(英文版)

摘　　要：To the Editor:Immune checkpoint inhibitors(ICIs)interact with critical factors involved in immunoregulation.Following the FDA approval of nivolumab as a second line therapy for unresectable hepatocellular carcinoma(HCC)in 2017,numerous HCC patients have experienced benefits from ICIs[1].In 2020,the FDA approved the combination of atezolizumab and bevacizumab as first line treatment for unresectable HCCs that have not undergone prior systemic treatments[2].ICIs are driving a transformative change in the field of cancer therapy.

关 键 词：approval IMMUNE treatment 

分 类 号：R735.7[医药卫生—肿瘤]